{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Inflammation", "Myocardial infarction", "Omega-3 polyunsaturated fatty acid", "hs-CRP"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "39073419", "DateRevised": {"Year": "2024", "Month": "07", "Day": "29"}, "Article": {"Language": ["eng"], "ELocationID": ["10.1007/s00210-024-03330-1"], "ArticleDate": [{"Year": "2024", "Month": "07", "Day": "29"}], "Journal": {"ISSN": "1432-1912", "JournalIssue": {"PubDate": {"Year": "2024", "Month": "Jul", "Day": "29"}}, "Title": "Naunyn-Schmiedeberg's archives of pharmacology", "ISOAbbreviation": "Naunyn Schmiedebergs Arch Pharmacol"}, "ArticleTitle": "Omega-3 fatty acids effectively mitigate high-sensitivity C-reactive protein (hs-CRP) biomarker of inflammation in acute myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial.", "Abstract": {"AbstractText": ["Myocardial infarction (MI) is considered an inflammatory disease and among the leading causes of death globally. An essential indicator of inflammation, high-sensitivity C-reactive protein (hs-CRP), is linked with the acute MI prognosis. We aimed to examine the impact of omega-3 polyunsaturated fatty acids (PUFAs) as an anti-inflammatory supplement on hs-CRP levels in acute MI patients. Sixty patients with acute MI participated in this randomized, placebo-controlled trial. For 30 days, patients were randomized to receive omega-3 PUFAs (2 g/day, N\u2009=\u200930) or placebo (N\u2009=\u200930) on top of guideline-directed medical therapy. An initial and endpoint measurement of hs-CRP was performed. We found that the hs-CRP levels in both omega-3 PUFAs and placebo groups remarkably decreased following 30 days of treatment (decreasing from 1.84 (2.3) and 1.3 (2.6) to 0.38 (0.54) and 0.63 (1.12) mg/dL, respectively; P\u2009<\u20090.001). Following the 30 days of treatment, the reducing impact of omega-3 PUFAs (\u2193 1.54 (1.98) mg/dL) on hs-CRP was more robust than the placebo group (\u2193 0.92 (1.57) mg/dL, P\u2009=\u20090.008). Furthermore, the WBC, cholesterol, LDL, and triglyceride levels were markedly decreased in omega-3 and placebo groups after 30 days of therapy (P\u2009<\u20090.001 for all). However, no remarkable differences were reported in the level of these parameters after 30 days of therapy between both studied groups. Our findings showed that omega-3 PUFAs decrease hs-CRP amounts in patients with acute MI. Omega-3 PUFA supplementation may be an appropriate candidate in patients with early-stage acute MI for inhibiting inflammation."], "CopyrightInformation": "\u00a9 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Ahmadi", "ForeName": "Mostafa", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Askari", "ForeName": "Vahid Reza", "Initials": "VR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Shahri", "ForeName": "Bahram", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Mousavi Noghab", "ForeName": "Seyed Mahdiar", "Initials": "SM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Community Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Jarahi", "ForeName": "Lida", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. baradaranrv@mums.ac.ir."}], "LastName": "Baradaran Rahimi", "ForeName": "Vafa", "Initials": "V"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "Naunyn Schmiedebergs Arch Pharmacol", "NlmUniqueID": "0326264", "ISSNLinking": "0028-1298"}}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Abdolahi M, Sarraf P, Javanbakht MH, Honarvar NM, Hatami M, Soveyd N, Tafakhori A, Sedighiyan M, Djalali M, Jafarieh A, Masoudian Y, Djalali M (2018) A novel combination of \u03c9-3 fatty acids and nano-curcumin modulates interleukin-6 gene expression and high sensitivity C-reactive protein serum levels in patients with migraine: a randomized clinical trial study. CNS Neurol Disord Drug Targets 17:430\u2013438", "ArticleIdList": ["29938621", "10.2174/1871527317666180625101643"]}, {"Citation": "AbuMweis S, Jew S, Tayyem R, Agraib L (2018) Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a meta-analysis of randomised placebo-control human clinical trials. J Hum Nutr Diet 31:67\u201384", "ArticleIdList": ["28675488", "10.1111/jhn.12493"]}, {"Citation": "Ajala ON, Everett BM (2020) Targeting inflammation to reduce residual cardiovascular risk. Curr Atheroscler Rep 22:66", "ArticleIdList": ["32880743", "10.1007/s11883-020-00883-3"]}, {"Citation": "Baradaran Rahimi V, Askari VR (2022) A mechanistic review on immunomodulatory effects of selective type two cannabinoid receptor \u03b2-caryophyllene. BioFactors (oxford, England) 48:857\u2013882", "ArticleIdList": ["35648433", "10.1002/biof.1869"]}, {"Citation": "Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380:11\u201322", "ArticleIdList": ["30415628", "10.1056/NEJMoa1812792"]}, {"Citation": "Campos-Staffico AM, Costa APR, Carvalho LSF, Moura FA, Santos SN, Coelho-Filho OR, Nadruz W Jr, Quinaglia ESJC, Sposito AC (2019) Omega-3 intake is associated with attenuated inflammatory response and cardiac remodeling after myocardial infarction. Nutr J 18:29", "ArticleIdList": ["31060562", "6503367", "10.1186/s12937-019-0455-1"]}, {"Citation": "Carrero JJ, Andersson Franko M, Obergfell A, Gabrielsen A, Jernberg T (2019) hsCRP level and the risk of death or recurrent cardiovascular events in patients with myocardial infarction: a healthcare-based study. J Am Heart Assoc 8:e012638", "ArticleIdList": ["31140334", "6585357", "10.1161/JAHA.119.012638"]}, {"Citation": "Dastani M, Rahimi HR, Askari VR, Jaafari MR, Jarahi L, Yadollahi A, Rahimi VB (2023) Three months of combination therapy with nano-curcumin reduces the inflammation and lipoprotein (a) in type 2 diabetic patients with mild to moderate coronary artery disease: evidence of a randomized, double-blinded, placebo-controlled clinical trial. BioFactors (oxford, England) 49:108\u2013118", "ArticleIdList": ["35674733", "10.1002/biof.1874"]}, {"Citation": "Denegri A, Boriani G (2021) High sensitivity C-reactive protein (hsCRP) and its implications in cardiovascular outcomes. Curr Pharm Des 27:263\u2013275", "ArticleIdList": ["32679014", "10.2174/1381612826666200717090334"]}, {"Citation": "Dirjayanto VJ, Martin-Ruiz C, Pompei G, Rubino F, Kunadian V (2024) The association of inflammatory biomarkers and long-term clinical outcomes in older adults with non-ST elevation acute coronary syndrome. Int J Cardiol 409:132177", "ArticleIdList": ["38761976", "10.1016/j.ijcard.2024.132177"]}, {"Citation": "Djuricic I, Calder PC (2021) Beneficial outcomes of omega-6 and omega-3 polyunsaturated fatty acids on human health: an update for 2021. Nutrients 13(7):2421", "ArticleIdList": ["34371930", "8308533", "10.3390/nu13072421"]}, {"Citation": "Doi M, Nosaka K, Miyoshi T, Iwamoto M, Kajiya M, Okawa K, Nakayama R, Takagi W, Takeda K, Hirohata S, Ito H (2014) Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study. Int J Cardiol 176:577\u2013582", "ArticleIdList": ["25305703", "10.1016/j.ijcard.2014.08.055"]}, {"Citation": "Elagizi A, Lavie CJ, O\u2019Keefe E, Marshall K, O\u2019Keefe JH, Milani RV (2021) An update on omega-3 polyunsaturated fatty acids and cardiovascular health. Nutrients 13(1):204", "ArticleIdList": ["33445534", "7827286", "10.3390/nu13010204"]}, {"Citation": "Fazlinezhad A, Dorri M, Azari A, Bigdelu L (2014) Frequency of ischemic mitral regurgitation after first-time acute myocardial infarction and its relation to infarct location and in-hospital mortality. J Tehran Heart Cent 9:160\u2013165", "ArticleIdList": ["25870640", "4394054"]}, {"Citation": "Gao Y, Wang M, Wang R, Jiang J, Hu Y, Wang W, Wang Y, Li H (2024) The predictive value of the hs-CRP/HDL-C ratio, an inflammation-lipid composite marker, for cardiovascular disease in middle-aged and elderly people: evidence from a large national cohort study. Lipids Health Dis 23:66", "ArticleIdList": ["38429790", "10908181", "10.1186/s12944-024-02055-7"]}, {"Citation": "Gholoobi A, Askari VR, Naghedinia H, Ahmadi M, Vakili V, Baradaran Rahimi V (2021) Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial. Inflammopharmacology 29:1379\u20131387", "ArticleIdList": ["34420187", "10.1007/s10787-021-00865-0"]}, {"Citation": "Hamilton-Craig C, Kostner K, Colquhoun D, Nicholls SJ (2023) Omega-3 fatty acids and cardiovascular prevention: is the jury still out? Intern Med J 53:2330\u20132335", "ArticleIdList": ["38105550", "10.1111/imj.16283"]}, {"Citation": "Hoogeveen EK, Geleijnse JM, Kromhout D, Giltay EJ (2014) No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: the Alpha Omega Trial. Eur J Prev Cardiol 21:1429\u20131436", "ArticleIdList": ["23774275", "10.1177/2047487313494295"]}, {"Citation": "Huang L, Zhang F, Xu P, Zhou Y, Liu Y, Zhang H, Tan X, Ge X, Xu Y, Guo M, Long Y (2023) Effect of omega-3 polyunsaturated fatty acids on cardiovascular outcomes in patients with diabetes: a meta-analysis of randomized controlled trials. Adv Nutr 14:629\u2013636", "ArticleIdList": ["37121469", "10334152", "10.1016/j.advnut.2023.04.009"]}, {"Citation": "Ishihara T, Yoshida M, Arita M (2019) Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis. Int Immunol 31:559\u2013567", "ArticleIdList": ["30772915", "10.1093/intimm/dxz001"]}, {"Citation": "Kandelouei T, Abbasifard M, Imani D, Aslani S, Razi B, Fasihi M, Shafiekhani S, Mohammadi K, Jamialahmadi T, Reiner \u017d, Sahebkar A (2022) Effect of statins on serum level of hs-CRP and CRP in patients with cardiovascular diseases: a systematic review and meta-analysis of randomized controlled trials. Mediators Inflamm 2022:8732360", "ArticleIdList": ["35125965", "8816584", "10.1155/2022/8732360"]}, {"Citation": "Khameneh Bagheri R, Najafi MN, Ahmadi M, Saberi M, Maleki M, Baradaran Rahimi V (2022) Investigation of the association between serum uric acid levels and HEART risk score in patients with acute coronary syndrome. Physiol Rep 10:e15513", "ArticleIdList": ["36394077", "9669611", "10.14814/phy2.15513"]}, {"Citation": "Leuti A, Fazio D, Fava M, Piccoli A, Oddi S, Maccarrone M (2020) Bioactive lipids, inflammation and chronic diseases. Adv Drug Deliv Rev 159:133\u2013169", "ArticleIdList": ["32628989", "10.1016/j.addr.2020.06.028"]}, {"Citation": "Liberale L, Montecucco F, Schwarz L, L\u00fcscher TF, Camici GG (2021) Inflammation and cardiovascular diseases: lessons from seminal clinical trials. Cardiovasc Res 117:411\u2013422", "ArticleIdList": ["32666079", "10.1093/cvr/cvaa211"]}, {"Citation": "Makarewicz-Wujec M, Parol G, Parzonko A, Koz\u0142owska-Wojciechowska M (2017) Supplementation with omega-3 acids after myocardial infarction and modification of inflammatory markers in light of the patients\u2019 diet: a preliminary study. Kardiol Pol 75:674\u2013681", "ArticleIdList": ["28394002", "10.5603/KP.a2017.0072"]}, {"Citation": "Martinez BK, White CM (2018) The emerging role of inflammation in cardiovascular disease. Ann Pharmacother 52:801\u2013809", "ArticleIdList": ["29557210", "10.1177/1060028018765939"]}, {"Citation": "Mason RP, Sherratt SCR, Eckel RH (2023) Omega-3-fatty acids: do they prevent cardiovascular disease? Best Pract Res Clin Endocrinol Metab 37:101681", "ArticleIdList": ["35739003", "10.1016/j.beem.2022.101681"]}, {"Citation": "Mohsen G, Stroemer A, Mayr A, Kunsorg A, Stoppe C, Wittmann M, Velten M (2023) Effects of omega-3 fatty acids on postoperative inflammatory response: a systematic review and meta-analysis. Nutrients 15(15):3414", "ArticleIdList": ["37571352", "10421202", "10.3390/nu15153414"]}, {"Citation": "Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Ridker PM, Ray KK, Katona BG, Himmelmann A, Loss LE, Rensfeldt M, Lundstr\u00f6m T, Agrawal R, Menon V, Wolski K, Nissen SE (2020) Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 324:2268\u20132280", "ArticleIdList": ["33190147", "7667577", "10.1001/jama.2020.22258"]}, {"Citation": "Oikonomou E, Vogiatzi G, Karlis D, Siasos G, Chrysohoou C, Zografos T, Lazaros G, Tsalamandris S, Mourouzis K, Georgiopoulos G, Toutouza M, Tousoulis D (2019) Effects of omega-3 polyunsaturated fatty acids on fibrosis, endothelial function and myocardial performance, in ischemic heart failure patients. Clin Nutr 38:1188\u20131197", "ArticleIdList": ["29752009", "10.1016/j.clnu.2018.04.017"]}, {"Citation": "Poggioli R, Hirani K, Jogani VG, Ricordi C (2023) Modulation of inflammation and immunity by omega-3 fatty acids: a possible role for prevention and to halt disease progression in autoimmune, viral, and age-related disorders. Eur Rev Med Pharmacol Sci 27:7380\u20137400", "ArticleIdList": ["37606147"]}, {"Citation": "Popoff F, Balaciano G, Bardach A, Comand\u00e9 D, Irazola V, Catalano HN, Izcovich A (2019) Omega 3 fatty acid supplementation after myocardial infarction: a systematic review and meta-analysis. BMC Cardiovasc Disord 19:136", "ArticleIdList": ["31164089", "6549284", "10.1186/s12872-019-1086-3"]}, {"Citation": "Poreba M, Rostoff P, Siniarski A, Mostowik M, Golebiowska-Wiatrak R, Nessler J, Undas A, Gajos G (2018) Relationship between polyunsaturated fatty acid composition in serum phospholipids, systemic low-grade inflammation, and glycemic control in patients with type 2 diabetes and atherosclerotic cardiovascular disease. Cardiovasc Diabetol 17:29", "ArticleIdList": ["29452596", "5815243", "10.1186/s12933-018-0672-5"]}, {"Citation": "Rahmanian-Devin P, Rakhshandeh H, Baradaran Rahimi V, Sanei-Far Z, Hasanpour M, Memarzia A, Iranshahi M, Askari VR (2021) Intraperitoneal lavage with Crocus sativus prevents postoperative-induced peritoneal adhesion in a rat model: evidence from animal and cellular studies. Oxid Med Cell Longev 2021:5945101", "ArticleIdList": ["34956439", "8702342", "10.1155/2021/5945101"]}, {"Citation": "Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ (2019) Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 380:752\u2013762", "ArticleIdList": ["30415610", "10.1056/NEJMoa1809798"]}, {"Citation": "Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119\u20131131", "ArticleIdList": ["28845751", "10.1056/NEJMoa1707914"]}, {"Citation": "Roman YM, Hernandez AV, White CM (2020) The role of suppressing inflammation in the treatment of atherosclerotic cardiovascular disease. Ann Pharmacother 54:1021\u20131029", "ArticleIdList": ["32425120", "10.1177/1060028020922994"]}, {"Citation": "Salman HB, Salman MA, Yildiz Akal E (2022) The effect of omega-3 fatty acid supplementation on weight loss and cognitive function in overweight or obese individuals on weight-loss diet. Nutr Hosp 39:803\u2013813", "ArticleIdList": ["35815739"]}, {"Citation": "Sethwala AM, Goh I, Amerena JV (2021) Combating inflammation in cardiovascular disease. Heart Lung Circ 30:197\u2013206", "ArticleIdList": ["33039279", "10.1016/j.hlc.2020.09.003"]}, {"Citation": "Shafiee-Nick R, Afshari AR, Mousavi SH, Rafighdoust A, Askari VR, Mollazadeh H, Fanoudi S, Mohtashami E, Rahimi VB, Mohebbi M, Vahedi MM (2017) A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 94:541\u2013556", "ArticleIdList": ["10.1016/j.biopha.2017.07.084"]}, {"Citation": "Siniarski A, Gajos G (2021) Polyunsaturated fatty acids in cardiovascular diseases: uncertainty prevails. Pol Arch Intern Med 131:716\u2013723", "ArticleIdList": ["34463083", "10.20452/pamw.16066"]}, {"Citation": "Siniarski A, Haberka M, Mostowik M, Go\u0142\u0119biowska-Wiatrak R, Por\u0119ba M, Malinowski KP, G\u0105sior Z, Konduracka E, Nessler J, Gajos G (2018) Treatment with omega-3 polyunsaturated fatty acids does not improve endothelial function in patients with type 2 diabetes and very high cardiovascular risk: a randomized, double-blind, placebo-controlled study (Omega-FMD). Atherosclerosis 271:148\u2013155", "ArticleIdList": ["29518747", "10.1016/j.atherosclerosis.2018.02.030"]}, {"Citation": "Wang Y, Wang Y, Shehzad Q, Su Y, Xu L, Yu L, Zeng W, Fang Z, Wu G, Wei W, Jin Q, Zhang H, Wang X (2023) Does omega-3 PUFAs supplementation improve metabolic syndrome and related cardiovascular diseases? A systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr: 1\u201328. https://doi.org/10.1080/10408398.2023.2212817"}, {"Citation": "Yuan M, Zhang Y, Hua T, Liu XL, Liu T, Yuan RY, Li GP, Zhu Y, Zhang X (2021) Omega-3 polyunsaturated fatty acid supplementation improves lipid metabolism and endothelial function by providing a beneficial eicosanoid-pattern in patients with acute myocardial infarction: a randomized, controlled trial. Clin Nutr 40:445\u2013459", "ArticleIdList": ["33041091", "10.1016/j.clnu.2020.05.034"]}]}], "History": [{"Year": "2024", "Month": "6", "Day": "26"}, {"Year": "2024", "Month": "7", "Day": "24"}, {"Year": "2024", "Month": "7", "Day": "29", "Hour": "12", "Minute": "42"}, {"Year": "2024", "Month": "7", "Day": "29", "Hour": "12", "Minute": "42"}, {"Year": "2024", "Month": "7", "Day": "29", "Hour": "11", "Minute": "2"}], "PublicationStatus": "aheadofprint", "ArticleIdList": ["39073419", "10.1007/s00210-024-03330-1", "10.1007/s00210-024-03330-1"]}}]}